NasdaqGS:MLYSBiotechs
Does New CMO Hire and Heavier Leverage Reshape the Bull Case For Mineralys Therapeutics (MLYS)?
In August 2026, Mineralys Therapeutics reported a second-quarter net loss of US$241.07 million and a six-month net loss of US$280.41 million, while also appointing veteran cardiologist and drug developer James J. “Terry” Ferguson III, M.D., as its new Chief Medical Officer with his predecessor moving into a full-time advisory role.
These developments came as the company advanced its lead therapy lorundrostat toward an expected FDA decision and bolstered its balance sheet with US$150 million...